Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034 is registered in ClinicalTrials.gov with Amylyx Pharmaceuticals Inc. as lead sponsor.

NCT NCT05676034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05676034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram Syndrome
Lead sponsor
Amylyx Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 3, 2023
Completion date
May 31, 2028
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

wolfram syndrome